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Abstract
A central goal in cancer genomics is to identify the somatic alterations that underpin tumor
initiation and progression. This task is challenging as the mutational profiles of cancer genomes
exhibit vast heterogeneity, with many alterations observed within each individual, few shared
somatically mutated genes across individuals, and important roles in cancer for both frequently
and infrequently mutated genes. While commonly mutated cancer genes are readily identifiable,
those that are rarely mutated across samples are difficult to distinguish from the large numbers
of other infrequently mutated genes. Here, we introduce a method that considers per-individual
mutational profiles within the context of protein-protein interaction networks in order to identify
small connected subnetworks of genes that, while not individually frequently mutated, comprise
pathways that are perturbed across (i.e., “cover”) a large fraction of the individuals. We devise
a simple yet intuitive objective function that balances identifying a small subset of genes with
covering a large fraction of individuals. We show how to solve this problem optimally using
integer linear programming and also give a fast heuristic algorithm that works well in practice.
We perform a large-scale evaluation of our resulting method, nCOP, on 6,038 TCGA tumor sam-
ples across 24 different cancer types. We demonstrate that our approach nCOP is more effective
in identifying cancer genes than both methods that do not utilize any network information as
well as state-of-the-art network-based methods that aggregate mutational information across
individuals. Overall, our work demonstrates the power of combining per-individual mutational
information with interaction networks in order to uncover genes functionally relevant in cancers,
and in particular those genes that are less frequently mutated.
Software download: http://www.cs.princeton.edu/∼mona/software/ncop.html
∗Department of Computer Science and Lewis-Sigler Institute for Integrative Genomics, Princeton University
†Email mona@cs.princeton.edu
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Introduction
Large-scale cancer genome sequencing consortia, such as The Cancer Genome Atlas (TCGA) [35],
the International Cancer Genome Consortium (ICGC) [37] and other smaller, cancer-specific studies
have sequenced the protein-coding regions of thousands of tumor samples across tens of different
cancer types. Initial analyses of these data have revealed that while there may be numerous somatic
mutations in a tumor that result in altered protein sequences, very few are likely to play a role
in cancer development [2, 14, 41]. Therefore, a major challenge in cancer genomics is to develop
methods that can distinguish the so-called “driver” mutations important for cancer initiation and
progression from numerous other “passenger” mutations.
Early statistical approaches have identified cancer-driving genes by highlighting those genes
that are mutated more frequently in a cohort of patients than expected by chance according to
some background model [10, 25, 44]. However, the genetic underpinnings of cancer are highly het-
erogeneous: even when considering a single cancer type, very few genes are found to be somatically
mutated across large numbers of individuals [18]. Further, genes altered only in a few individuals
may also be important for tumorigenesis and cancer progression [34]. Clearly, these rarely mutated
but cancer-relevant genes cannot be detected by purely frequency-based approaches.
A promising alternative viewpoint is to consider somatic mutations in the context of pathways
instead of genes. In particular, it has been proposed that alterations within any of several genes
comprising the same pathway can have similar consequences with respect to cancer development,
and that this contributes to the mutational heterogeneity evident across cancers. Consistent with
this, numerous analyses of TCGA data have shown that certain known pathways are frequently
altered across tumor samples of a particular cancer via mutations in different genes [28, 36]. Early
studies have leveraged this observation by analyzing known pathways for enrichment of somatic
mutations [4, 21] and pinpointing those that are significantly mutated across patients [40, 42]. The
power of these studies is somewhat limited, however, as our knowledge of pathways is incomplete
and new pathways cannot be identified by these approaches.
De novo discovery of cancer-relevant pathways using large-scale protein interaction networks
has thus been the focus of several newer methods (e.g., [4, 5, 7, 29, 39]). In particular, since
protein-protein interaction networks have a modular organization [15, 32], proteins taking part in
the same pathways and processes tend to be close to each other in the network. One prominent
class of techniques leverages this modular structure by propagating mutational information through
protein interaction networks and deriving pathways from the induced subnetworks [1, 20, 26, 39].
For instance, Vandin et al. [39] diffuse a “heat” signal arising from the frequency with which
proteins are somatically mutated across a cohort of samples to uncover cancer-relevant modules
while Hofree et al. [17] approach the problem from a different angle, using biological network
information to stratify cancer subtypes. A recent pan-cancer network analysis [26] affirms the
power of diffusing mutational data across protein interaction networks, especially for uncovering
rarely mutated cancer genes. However, such diffusion approaches can be highly influenced by
frequently mutated genes [26], and further, these methods do not consider whether most patients
have mutations in any of the identified pathways.
Here we present a novel network-based approach to tackle cancer mutational heterogeneity
by utilizing per-individual mutational profiles. Our method is based on the expectation that if a
pathway is relevant for cancer, then (1) many individuals will have a somatic mutation within one of
the genes comprising the pathway and (2) the genes comprising the pathway will interact with each
other and together form a small connected subcomponent within the larger network. Therefore,
given a biological network as well as patient sample data consisting of somatic point mutations,
the goal of our approach is to find a set of candidate genes that both “cover” the most patients
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(i.e., individuals have mutations in one or more of these genes) and are connected in the network
(i.e., these genes are likely to participate in the same cellular pathway or process). In contrast to
network diffusion approaches, our framework focuses on per-individual mutational profiles and as
a result, the “influence” of frequently mutated genes is not spread through the network. We note
that network-based coverage approaches have been previously introduced to uncover pathways that
are dysregulated [6, 23, 38] or mutated [9, 24] across cohort of samples. However, either patients
were required to be covered by these approaches [6, 23, 24, 38], in some cases multiple times
(which is especially relevant for dysregulated genes, since there many of them), or these approaches
were designed for data sets with significantly fewer mutations [9]; both cases lead to very different
optimizations and algorithms that are not effective for the task at hand.
We devise a simple yet intuitive objective function that balances identifying a small subset of
genes with covering a large fraction of individuals. Our objective has just a single parameter that
is automatically set using a series of cross-validation tests, eliminating the need of many previous
approaches to manually select values for various thresholds and parameters. We develop an integer
linear programming formulation to solve this problem and also give a fast heuristic algorithm. We
apply our method—network-based coverage of patients (nCOP)—to 24 cancer types from TCGA
and uncover both well-known cancer driver genes as well as new potential cancer-related genes. We
compare nCOP to previous methods that do not use network information, including a state-of-the-art
frequency-based method [25] and a “set cover” version of our approach that attempts to find a set of
genes that covers cancer samples without considering network connectivity, and demonstrate nCOP’s
superior power in detecting known cancer genes and in zooming in on rarely mutated ones. Finally,
we compare nCOP to a recent network-based method that aggregates mutational information [5]
and show that our per-patient approach readily outperforms it.
Methods
Overview. In this section, we give an overview of our methodology (see also Supplementary
Figure 1); each part is described in more detail in the subsequent sections.
The biological network is modeled as an undirected graph G where each vertex represents a
gene, and there is an edge between two vertices if an interaction has been found between the
corresponding proteins. We annotate each node in the network with the IDs of the individuals
having one or more mutations in the corresponding gene. Our goal is to find a relatively small
connected component G′ such that most patients have mutations in one of the genes within it. A
small subgraph is more likely to consist of functionally related genes and is less likely to be the
result of overfitting to the set of individuals whose diseases we are analyzing. However, we would
also like our model to have the greatest possible explanatory power—that is, to account for, or
cover, as many patients as possible by including genes that are mutated within their cancers. We
formulate our problem to balance these two competing objectives with a parameter α that controls
the trade-off between keeping the subgraph small and covering more patients.
For a fixed value of α, we have developed two approaches to solve the underlying optimization
problem. One is based on linear programming and the other is a fast greedy heuristic (see below).
We use the greedy heuristic in the context of a carefully designed cross-validation procedure to
automatically select a value for α that results in good coverage of patients but avoids overfitting
to them. Once α is selected, this value is used within our objective function and we next analyze
the entire patient cohort. In particular, multiple independent trials using α are run on randomly
chosen subsets of the patient data, as we have found that introducing a little bit of randomness
helps increase performance as compared to a single run on the full data set. Each trial outputs
a subgraph, and our final aggregated output is an ordered list of candidate genes ranked by how
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frequently each has been selected over the trials.
General formulation. Each vertex vj is associated with a set Cj containing the IDs of the
individuals who have somatic mutations in the corresponding gene. A patient with ID i is covered
if i ∈ ⋃
vj∈G′
Cj , and uncovered otherwise. We formulate our problem as that of finding a connected
subgraph G′ of G so as to minimize
αX + (1− α)Size(G′),
where X is the fraction of patients that do not have an alteration in a gene included in G′ (i.e., they
are uncovered), Size(G′) is the size of the subgraph, and 0 ≤ α ≤ 1 is a fixed parameter controlling
the trade-off between keeping the subgraph G′ small and covering more patients. We note that
our problem is similar, though not identical, to the Minimum Connected Set Cover Problem [31],
a NP-hard problem.
A simple and natural measure for the size of a subnetwork is its number of nodes (i.e., Size(G′) =
|G′|). However, longer genes may tend to acquire more mutations simply by chance. We correct
for that by associating with each node vj a weight wj that is equal to the ratio of the length of
the gene to the total number of mutations it has. The size of the subcomponent is then defined
as Size(G′) =
∑
vj∈G′
wj . This way, genes having longer length will be weighted more, correcting for
a possible bias towards selecting longer genes. We note that since our objective function balances
the fraction of uncovered patients with the size of the graph, we would like the size of the graph
to be between 0 and 1; thus, we normalize each node weight by dividing by the unnormalized size
of what we call a fully covering subgraph Gf—a connected subgraph of G that covers all patients.
(In practice, we compute Gf using the greedy heuristic described below, with α = 1).
Integer linear programming formulation. The problem of finding a minimum connected
subgraph that covers as many patients as possible can be solved using constraint optimization. Let
n be the number of patients in our sample. For each patient i, we define a binary variable pi that
is set to 1 if patient i is covered by the chosen subgraph G′, and 0 otherwise. For each vertex
(or gene) vj , we define a binary variable xj that is set to 1 if the vertex is included in the chosen
subgraph G′, and 0 otherwise. It is straightforward to set up constraints to ensure that a patient
is considered uncovered if none of its mutated genes are part of G′, and covered if at least one of
its mutated genes is selected as part of G′ (see Equations (1) and (2) below).
The challenging part of the ILP is setting up constraints to ensure that the chosen nodes form
a connected subgraph G′. For this task, we employ a flow of commodity technique [11], which we
now briefly describe. We inject |G′| units of flow into G′ (i.e., we inject ∑xi units of “flow” into
a vertex that is included in the chosen subnetwork). Flow can move from one vertex to any of
its neighbors in the network, and each vertex removes exactly one unit of flow as the flow passes
through it. All flow must be removed from the subnetwork, and we set the constraints so that this
is possible only if the subnetwork G′ is connected. For the source of the flow we use an artificial
external node vextr. The main issue is that we do not know which node vextr should be connected
to, as we do not know the nodes of G′ in advance. To resolve this, we decide that vextr connects
to the node that covers the largest number of patients vmax; this is equivalent to determining in
advance that vmax ∈ G′, though as an alternate approach we could also decide to choose this node
probabilistically and run the ILP several times. Finally, to handle the flow constraints, for each
edge (i, j) ∈ E, we introduce integer variables yi,j and yj,i to represent the amount of flow from
node i to node j and from node j to node i, respectively. The full integer linear program is:
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minimize α(n−∑
i
pi)/n+ (1− α)
∑
j
xjwj
subject to
pi ≥ xj ∀i, j s. t. i ∈ Cj (1)
pi ≤
∑
j:i∈Cj
xj for each patient i (2)∑
i:(i,j)∈E
yi,j = xj +
∑
i:(i,j)∈E
yj,i for each vertex vj (3)∑
j:(i,j)∈E
yi,j ≤ |V |xi for each vertex vi (4)∑
i
xi = yextr,max (5)
pi, xi, yi,j ∈ {0, 1} for all such variables (6)
Equation (1) ensures that a patient is considered covered if one of his or her or somatically mutated
genes is included in G′. Equation (2) ensures that a patient is not considered covered if none of his
or her somatically mutated genes is chosen to be part of the subgraph. Equations (3), (4) and (5)
enforce the connectivity requirement. Equation (3) requires that the flow going out of each vertex
in the chosen subnetwork is 1 less than the flow coming in. Equation (4) requires that if a vertex
is not part of the chosen subgraph, the flow going through it is 0. Equation (5) sets the amount of
flow injected into the subgraph to be equal to the number of chosen nodes.
Greedy heuristic. Solving the ILP yields an exact solution but is computationally difficult.
Thus, we have also developed an efficient greedy heuristic. Our heuristic procedure initializes G′
by randomly choosing the first gene from among the five most mutated genes, with probability
proportional to the number of patients it is found mutated in. It then expands the subgraph G′
iteratively as follows. At each iteration, all vertices that are at most distance 2 from a vertex
in G′ are examined and the one that improves the objective function the most is chosen; any
ties are broken uniformly at random. If this vertex is not directly adjacent to the nodes in the
subnetwork, the intermediary node is also added. The heuristic terminates when no improvement
to the objective is possible. We repeat this heuristic multiple times, as it is probabilistic.
In practice, the greedy heuristic finds a solution that is on average ∼90% of the best value for
the objective function as determined by the ILP formulation using CPLEX [19]. For example, on the
glioblastoma dataset of 277 individuals, the ILP finds 61 genes covering 90% of the patients when
using α=0.5. In comparison, for this value of α, the greedy heuristic finds on average 66 genes
covering 88% of the patients. In the rest of the paper, we use the greedy optimization as it has
comparable performance to the ILP, while being much faster.
Parameter selection and solution aggregation. Our approach to uncover a subnetwork of
mutated genes that covers many patients has a single parameter, α. Large values of α result in a
larger number of selected genes that cover more patients, yet may contain more irrelevant genes;
this may especially be a factor in the current analysis if there are many samples where missense
mutations are not the driving event. We devised a simple but effective data-driven cross-validation
technique to choose an appropriate α for a set of cancer samples. In particular, we split our samples
into training, validation and test sets [16]. A test set of (10%) of the patients is completely withheld.
While varying α in small increments in the interval (0; 1), the remaining data is repeatedly split
(100 times for each value of α) into training (80%) and validation (20%) sets. For each split, the
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greedy heuristic algorithm is run on the training set to find G′. The fractions of patients covered
(by the selected G′) in the training and validation sets are compared. The parameter α is selected
where performance on the validation sets deviates as compared to the training sets. While this
can be done visually, for all results reported here we do this automatically using a simple two-rule
procedure that selects the smallest α for which the difference in average coverage between the
training and validation set exceeds 5% and for which average performance on the validation set is
within 10% from the maximum observed one for any α. Finally, the coverage of patients on the
(completely withheld) test set is computed to ensure it is similar to the one on the validation set.
Once α is chosen for a set of cancer samples, we repeatedly (1000 times) run the algorithm
on this set, each time withholding a fraction (15%) of the patients in order to introduce some
randomness in the process. Genes are then ranked by the number of times they appear in G′. In
practice, we have found that this improves performance as compared to running the algorithm once
on the full data set.
Data sources and pre-processing. We downloaded all level 3 cancer somatic mutation data
from The Cancer Genome Atlas (TCGA) [35] that was available as of October 1, 2014. This data
consists of a total of 19,460 genes with somatic point mutations across 24 cancer types. For each
cancer, samples that are obvious outliers with respect to their total number of mutated genes are
excluded. See Supplementary Table 1 for a list of the cancer types, the cancer-specific thresholds
to determine outlier samples, the number of patient samples considered for each cancer type, and
other statistics about the TCGA somatic mutation dataset.
We use two different biological networks in our analysis: HPRD [30] (Release 9 041310) and
BioGrid (Release 3.2.99, physical interactions only) [33]. Biological networks can exhibit several
nodes with very high connectivity, often due to study bias. As such high connectivity destroys the
usefulness of the network information, we remove all nodes whose degrees are clear outliers. For
BioGrid, this removes UBC, APP, ELAVL1, SUMO2, CUL3. For HPRD, this removes no nodes.
For both networks, we exclude the nine longest genes (TTN, MUC16, SYNE1, NEB, MUC19,
CCDC168, FSIP2, OBSCN, GPR98 ) as they tend to acquire numerous mutations by chance while
covering many patients.
To further handle the connectivity arising within the networks due to high-degree nodes, we
filter edges using the diffusion state distance (DSD) metric introduced in [3]; the DSD metric
captures the intuition that edges between nodes that also share interactions with low degree nodes
are more likely to be functionally meaningful than edges that do not (and thus are assigned closer
distances). For each edge, the DSD scores (as computed by the software of [3]) between the
corresponding nodes are Z-score normalized, and edges with Z-scores > 0.3 are removed. We note
that the overall performance of our approach improves when performing this filtering (data not
shown), supporting the claim of [3] that preprocessing a biological network in this manner is an
important step. The final number of nodes and edges, respectively, for the filtered networks are
9,379 and 36,638 for HPRD ; and 14,326 and 102,552 for BioGrid.
Other approaches. To ascertain the contribution of network information, we compare nCOP to two
approaches that do not use network information: (1) MutSigCV 2.0 [25], a state-of-the-art method
that identifies genes that are mutated more frequently than expected according to a background
model, and (2) a set cover approach that tries to find mutated genes that simply cover as many
patients as possible. We formulate the set cover approach as an ILP that tries to find a good cover
consisting of k vertices. Using the same notation as for nCOP, the set cover objective is to maximize∑
i
pi, subject to Equations (1) and (2) of nCOP, and with the additional constraints that
∑
j
xj ≤ k
and
∑
j
xj ≥ k. We also compare nCOP to HOTNET2 [26] and Muffinn [5], two recent network-
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based approaches that aggregate mutational information. All comparisons are made when running
on exactly the same cancer and (if used) network data. MutSigCV 2.0, Hotnet2 and Muffinn are
run with default parameters.
Performance evaluation. To evaluate the gene rankings of all the tested methods, we use the
curated list of 517 cancer census genes (CCGs) available from COSMIC [13]. All genes in this list
are considered as positives, and all other genes are considered as negatives. Though we expect
that there are genes other than those already on the CCG list that play a role in cancer, this is
a standard approach to judge performance (e.g.,see [20]) and gives us an idea of how methods are
performing as cancer genes should be highly ranked by methods that perform well. Since only the
top predictions by any method are relevant for cancer gene discovery, we judge performance by
computing the area under the precision-recall curve (AUPRC) using the top 100 genes predicted
by each method. If a method returns less than 100 genes, we extend the precision-recall curve to
100 genes assuming that it performs as a random classifier. We note that reasonable changes to
the number of predictions considered does not change our overall conclusions (data not shown).
Results
We run nCOP, using the greedy heuristic algorithm, on somatic point mutation data from 24
different TCGA cancer types. Results in the main paper use the HPRD network [30] for all
analysis and show some results using kidney renal clear cell carcinoma (KIRC) with 416 samples
as an examplar.
Increasing patient coverage while preventing overfitting. We first demonstrate that, across
the 24 cancer types, our training-validation-test set framework is a highly effective approach for
choosing an α that balances patient coverage with subnetwork size. For all cancers, when using
somatic missense mutation data, as α increases, the total number of genes in the chosen subnetwork
G′ increases (as expected), as does the fraction of patients in the training set that are covered
by these genes (Figure 1a and Supplementary Figure S2). For smaller values of α, coverage on
the validation sets closely matches that obtained on the training sets; that is, the sets of genes
chosen using patients in the training sets are also effective in covering patients in the corresponding
validation sets. For KIRC, when α = 0.5, genes chosen using the training sets cover on average
nearly 70% of patients in the corresponding validation sets. The fact that a small subnetwork can
be found that covers a large fraction of previously unseen patients is consistent with the hypothesis
that a shared pathway or process plays a role in most (but not all) of these patients’ cancers.
For larger values of α (> 0.6 for KIRC), however, coverage on the validation sets lags behind
that observed on the training sets. For even larger values of α (> 0.85 for KIRC), the algorithm
selects many genes, and eventually increases the coverage for most cancers on the training sets to
nearly 100%. However, larger values of α do not substantially increase coverage of the withheld
patients. This difference between the training and validation curves captures the overfitting of the
model and also illustrates the trade-off between covering more patients and keeping the solution
parsimonious. We note that the eventual plateau of the validation curve is consistent across cancer
types (Supplementary Figure S2) and on different networks (data not shown). For each cancer
type, values of α are selected by our automated procedure (see Methods); this value is α = 0.5 for
the KIRC dataset shown in Figure 2a.
As a control, we repeat the same procedure using only synonymous mutations (Figure 1b).
We observe that the coverage on the validation sets is much poorer. Though coverage of course
increases as more nodes are added, it never exceeds 50% even when α is increased to 1 or when
we have nearly perfect coverage on the training set, despite adding many more nodes. This poor
performance is consistent with the expectation that synonymous mutations do not result in altered
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Figure 1: Fraction of individuals covered as α varies. We illustrate our cross-validation procedure
for parameter selection using the KIRC data set and the HPRD protein-protein interaction network. For
each random split of the individuals, we run our algorithm on the training sets for different values of α, and
plot the fraction of covered individuals in the training (blue) and validation (red) sets. We also give the
number of proteins in the uncovered subgraphs G′ (orange). For each plotted value, the mean and standard
deviation over 100 random splits are shown. (a) When using somatic missense mutations, at higher values of
α, overfitting occurs as the coverage on the validation set levels while coverage on the training set continues
to increase. The parameter α is selected using an automated heuristic procedure (green rhombus) so that
coverage on the validation set is good while overfitting on the training set is not extreme. (b) When using
somatic synonymous mutations, there is poor coverage on the validation set regardless of coverage on the
training set. Further, as compared to using missense mutation data, significantly more genes are required to
cover the same fraction of individuals.
protein sequences and do not disturb cellular pathways. Hence, given the differences observed
between using missense versus silent mutation data when varying settings for α and comparing
training and validation sets, our formulation appears to be well-suited for extracting cancer-relevant
information from mutational profiles and interaction networks.
nCOP effectively uses network information to uncover known cancer genes. Having
shown in the previous section how to select a value for the only parameter in the model and having
demonstrated that our formulation is effective in choosing genes that are mutated in previously
unobserved patient samples, we next evaluate nCOP’s performance in predicting cancer genes.
We first consider how well nCOP recapitulates known cancer genes (CCGs) [12]. We find that
on KIRC, our top predictions include a high fraction of CCG genes (Figure 2). For example, genes
that are always output are VHL, PTEN, and BAP1, three well-known cancer genes. Other known
cancer genes such as JUN, BLM and ARID1A, are also highly ranked.
We next illustrate the power of our network-based method by comparing its performance on
the KIRC data set to approaches that do not consider network information (Figure 2). First,
we consider a set cover version of our approach that does not use network information at all.
We find that for the same number of predicted genes, our approach consistently has a larger
fraction of CCGs, demonstrating the advantage of using network information. We also considerably
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outperform a state-of-the-art frequency-based approach, MutSigCV 2.0 [25].
We next compare nCOP to these two non-
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
llllllll
llllllll
llllllllllllllllll
lllllllllllllllllllll
lllllllllll
lllllll
0.0
0.2
0.4
0.6
0.8
1.0
0 25 50 75 100
Number of genes considered
Fr
a
ct
io
n 
of
 g
en
es
 th
at
 a
re
 C
CG
s
l
nCOP
Set Cover
MutSigCV
Figure 2: nCOP is more successful than network-
agnostic methods in identifying known cancer
genes on the KIRC dataset. Our network-based al-
gorithm nCOP, a set cover version of our algorithm that
ignores network information, and MutSigCV 2.0, a
frequency-based approach, are compared on the KIRC
dataset. nCOP ranks genes based on how frequently
they are output, and MutSigCV 2.0 ranks genes by
q-values. The set cover approach is run for increas-
ing values of k until all patients are covered. For each
method, as an increasing number of genes are consid-
ered, we compute the fraction that are CCGs. Over
a range of thresholds, our algorithm nCOP outputs a
larger fraction of CCG genes than the other two ap-
proaches.
network approaches across all 24 cancer types.
In particular, we compute the log ratio of the
area under the precision recall curve (AUPRC)
of our approach versus each of the other ap-
proaches on each cancer type (Figure 3). We
outperform MutSigCV 2.0 in 21 of the 24 can-
cers and the set cover approach in all can-
cers, demonstrating the clear advantage of us-
ing network information; the performance im-
provement of nCOP over the set cover approach
is particularly notable as the main difference
of these approaches is the additional use of
network information by nCOP. In several can-
cers, the performance improvements of nCOP
are substantial. For example, nCOP shows a
four-fold improvement over MutSigCV 2.0 in
predicting cancer genes for liver hepatocellu-
lar carcinoma (LIHC) and a nearly eight-fold
improvement over MutSigCV 2.0 on pheochro-
mocytoma and paraganglioma (PCPG). Im-
portantly, nCOP uncovers rarely mutated CCGs
genes that network-agnostic methods fail to.
For instance, KLF6 and TCF7L2, mutated re-
spectively in only one and two individuals in
LIHC, and WT1, mutated in two individu-
als in PCPG, are all uncovered by nCOP be-
cause of their proximity to other mutated genes
in the network. In contrast, frequency-driven
MutSigCV 2.0 and network-agnostic set cover
both fail to uncover these CCG genes. We note
that the suboptimal performance of nCOP in the case of uterine carcinosarcoma (UCS) is due to
the fact that for this particular data set, two genes TP53 and FBXW7 cover 85% of the patients,
with only four genes being sufficient to cover 95% of the patients. This renders nCOP incapable
to effectively leverage network information as it returns only four genes. Nevertheless, the overall
superior performance of nCOP as compared to these two non-network based approaches on the vast
majority of cancers demonstrates its considerable power.
Having shown that nCOP better identifies cancer-relevant genes than two approaches that do not
use network information, we next consider whether the specific way in which nCOP uses network
information is beneficial. Towards this end, we compare the effectiveness of nCOP in uncovering
cancer genes to Muffinn [5], a method published within the last year that considers mutations
found in interacting genes. We find that in 20 out of the 24 cancer types, nCOP outperforms
Muffinn (Figure 4). We also compare nCOP to Hotnet2 [26], a cutting-edge network diffusion
method. As Hotnet2 does not output a ranked list of genes, we could not compute the area
under the precision recall curve. Instead, examining the complete list of genes highlighted by both
methods, we observe that nCOP exhibits significantly better precision while trailing slightly in recall
(Supplementary Figure S3).
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nCOP reveals novel genes, including those that are rarely mutated. In addition to ranking
known cancer genes highly, nCOP also gives high ranks to several non-CCG genes that may or may
not be implicated in cancer, as our knowledge of cancer-related genes is incomplete. We observe
that non-CCG that are highly ranked by nCOP tend to be less frequently mutated. For example,
among these novel predictions for KIRC are SALL1, NR5A2, and UBE2A which have all recently
been implicated to play a role in cancers [27, 43, 45].
When we consider the proteins out-
Set Cover MutSigCV
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Figure 3: Comparison of nCOP to two network-
agnostic methods across 24 cancer types. For each
of the 24 cancer types, we compute AUPRCs for nCOP, the
set cover approach, and MutSigCV 2.0 using their top 100
predictions. We give the log2 ratios of nCOP’s to set cover’s
AUPRCs (left panel) and of nCOP’s to MutSigCV 2.0’s
AUPRCs (right panel). Our approach nCOP outperforms the
set cover approach on all 24 cancers, and outperfoms both
network-agnostic methods on 21 out of 24 cancer types.
put by our procedure in at least half the
runs for KIRC, we find that they are en-
riched in many KEGG and GO pathways
relevant for cancer, including MicroRNAs
in cancer, Choline metabolism in cancer,
Central carbon metabolism in cancer and
PI3K-Akt signaling pathway (Bonferroni-
corrected p < 0.001, hypergeometric test).
When we remove all known CCG genes
and consider only new predictions, thus
performing a much harder test, only one
pathway, Thyroid hormone signaling path-
way, is enriched. Interestingly, it has been
shown that thyroid hormones play a role
in kidney growth and development [22]
and four of our non-CCG predictions are
part of that pathway, together with four
known cancer genes. Interestingly, two
of the non-CCG genes we find in this
pathway are rarely mutated, and are not
highlighted by MutSigCV 2.0 or set cover.
This illustrates the power of nCOP to zoom
in on potentially cancer-relevant modules
consisting of rarely mutated genes.
Potential biases, performance on
randomized data, and robustness.
Due to space and time constraints, we
briefly describe some additional tests we
performed to show that nCOP is robust and
well-behaved. First, we have tested nCOP
on another network and have shown that
it remains effective in identifying CCGs
(Supplementary Figures S4). Second, to
confirm the importance of network structure to nCOP, we have run nCOP on two types of random-
ized networks, degree-preserving and label shuffling, and have shown that (as expected) overall
performance deteriorates across the cancer types (Supplementary Figure S5); we note that though
network structure is destroyed, per-gene mutational information is perserved, and so highly mu-
tated genes are still output. Third, to make sure that the novel genes we uncover are not driven by
patients with large numbers of passenger mutations (i.e., that the novel genes are not likely to be
passenger genes), we have compared the overall number of mutations for patients having missense
9
mutations only in CCG genes but not in any predicted non-CCG (or novel) genes to the total
number of such mutations for patients having missense mutations only in novel genes but not in
any CCG genes (Supplementary Figure S6), and have found that patients with only mutations in
novel genes do not harbor more mutations. Finally, to make sure that genes are not more likely to
be picked because they have higher degree, we have confirmed that newly predicted do not tend
to exhibit higher degree than known cancer genes; indeed, among all novel genes found across all
cancer types, most have degree between < 15, and there are only a couple with high degree (≥ 50).
Discussion
In this paper, we have shown that nCOP, a method that incorporates individual mutational profiles
with protein–protein interaction networks, is a powerful approach for uncovering cancer genes.
Our method is based on an intuitive mathematical formulation and demonstrates higher precision
than other state-of-the-art methods in detecting known cancer genes. Further, our approach is
particularly beneficial in highlighting infrequently mutated genes that are nevertheless relevant for
cancer. Our approach therefore complements existing frequency-based methods (e.g., [25]) that
generally rely on comparisons to background mutational models and lack the statistical power to
detect genes mutated in fewer individuals.
In the future, nCOP can be extended in a number ofmuffinn
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Figure 4: Comparison of nCOP to
Muffinn. For each of the 24 cancers,
we compute the log2 ratio of nCOP’s to
Muffinn’s AUPRCs for their top 100 pre-
dictions. Our approach nCOP outperforms
Muffinn, a recent network-based approach,
on 20 out of 24 cancer types.
natural ways. First, while nCOP currently analyzes only
mutations within genes that affect protein coding, other
alterations are also commonly observed in cancers. For
example, copy number variants (CNVs) are found fre-
quently in cancers and can play critical functional roles
[46]. Although nCOP does not currently use CNV infor-
mation, our framework can be extended to incorporate
this data. Indeed, as the numbers of CNVs and point
mutations found within each cancer genome appear to be
inversely related [8], considering both types of alterations
will increase the power of our approach. Second, nCOP
may also benefit from incorporating gene weights that
reflect its likelihood to play a role in cancer; in our cur-
rent work, we consider a gene’s length but no other gene-
specific attributes are considered. Such gene weights may
be derived from existing approaches to detect frequency
of mutation or to assess the functional impact of muta-
tions. Finally, while nCOP can output groups of genes
that are not part of a single connected component due to
our randomized aggregation procedure, extending nCOP’s
core algorithms to explicitly consider multiple subnet-
works corresponding to distinct pathways may be a par-
ticularly promising avenue for future work.
We conclude by noting that researchers can use our
framework to rapidly and easily prioritize cancer genes, as nCOP requires only straightforward
inputs and runs on a desktop machine. Indeed, nCOP’s efficiency, robustness, and ease of use make
it an excellent choice to investigate cancer as well as possibly other complex diseases. As sequencing
costs plummet and cancer and other disease sequencing mutational data become more abundant,
the predictive power of our method should only increase. In sum, we expect that our method nCOP
will be of broad utility, and will represent a valuable resource for the cancer community.
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Supplementary Tables and Figures
The following pages contain a table summarizing the TCGA data we use along with 6 supplementary figures
that support the findings of the main paper.
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Cancer Number	of 								Number	of	Mutated	Genes
Symbol Cancer	Type Patients Total Average Cut	off	
ACC Adrenocortical	carcinoma 76 2068 32.1 80
BLCA Bladder	Urothelial	Carcinoma 196 11407 135.7 300
BRCA Breast	invasive	carcinoma 882 10813 27 80
CESC
Cervical	squamous	cell	carcinoma	and	
endocervical	adenocarcinoma 173 6907 63 200
COAD Colon	adenocarcinoma 153 6521 74.4 150
GBM Glioblastoma	multiforme 278 7250 46.8 80
HNSC Head	and	Neck	squamous	cell	carcinoma 435 13048 87.9 200
KICH Kidney	Chromophobe 64 661 11 50
KIRC Kidney	renal	clear	cell	carcinoma 416 9212 40.9 100
KIRP Kidney	renal	papillary	cell	carcinoma 166 5687 47.7 100
LGG Brain	Lower	Grade	Glioma 451 7130 28.8 60
LIHC Liver	hepatocellular	carcinoma 196 7705 67.3 200
LUAD Lung	adenocarcinoma 487 15481 172.8 500
LUSC Lung	squamous	cell	carcinoma 167 12264 212 500
OV Ovarian	serous	cystadenocarcinoma 138 3390 30.7 80
PAAD Pancreatic	adenocarcinoma 124 3228 36.8 100
PCPG Pheochromocytoma	and	Paraganglioma 183 1819 11.7 30
PRAD Prostate	adenocarcinoma 238 4792 28.1 50
READ Rectum	adenocarcinoma 34 1214 40.7 150
SKCM Skin	Cutaneous	Melanoma 329 14748 240.1 1000
STAD Stomach	adenocarcinoma 242 10595 103.5 500
THCA Thyroid	carcinoma 401 2268 7.4 30
UCEC Uterine	Corpus	Endometrial	Carcinoma 155 4282 38.8 100
UCS Uterine	Carcinosarcoma 54 1787 38.9 80
Table S1: TCGA dataset and statistics. We list the 24 cancer types studied along with their
abbreviations. For each cancer type, we give the total number of patient samples considered after
highly mutated samples are filtered out, the total number of mutated genes across these samples,
the average number of mutated genes across all samples, and the cutoff on the number of mutated
genes within a sample that was used to filter samples.
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TCEB1 PTEN 
ATXN1 
1. Withhold 10% of patients as test set. 
 
2. For 0 < α < 1: 
 
 
 
 
 
 
 
 
 
 
 
 
3. Select α with good performance. 
 
4. Verify against test set. 
 
a 
P1  ..GATTCAAGCAT..	
P2  ..GATTGAATCAT..	
P3  ..GATTCAATCAA.. 
	
PN  ..GAAACAATCAA.. 
	
...	
SVIL 
TBC1D 
CCR5 
TP53 
SPG2 
MTOR 
RHEB 
AKT1 
P1 
P2,P4 
P1 
P3,P5 
P3 
P3 
P1,P6,P7 
P1 
Label each node (i.e., gene) in a biological network G with the IDs of 
patients containing 1+ mutations in that gene.  
b Empirically assign parameter α: 
§  Split patients into training (80%) 
and validation (20%) sets. 
§  Find connected subgraph G’ 
covering the patients in the 
training set 
 
 
 
 
 
 
 
§  Verify against validation set. 
re
pe
at
 1
00
 ti
m
es
  
§  Select 85% of patients to add randomness. 
§  Find connected subgraph G’ using these 
patients.  
 
 
 
 
 
 
 
re
pe
at
 1
00
0 
tim
es
  
Iteratively find G’ using selected optimal α,  
keeping track of genes selected in G’:  
 
Rank Gene Name 
% Times 
Found in G’ 
Patients 
Covered 
1 TP53 93% P1, P6, P7... 
2 PTEN 88% P3, P5... 
3 MTOR 84% P2, P4... 
4 RHEB 84% P1... 
5 SVIL 68% P3... 
6 SPG2 52% P3... 
Aggregate results across iterations: c d 
Figure S1: Overview of our approach. (a) Somatic mutations are mapped onto a protein-protein
interaction network. Each node is associated with the set of individuals whose cancers have mutations in the
corresponding gene. The overall goal is to select a small connected subnetwork such that most individuals
in the cohort have mutations in one of the corresponding genes (i.e., are “covered”). (b) nCOP automatically
selects a value for the parameter α by performing a series of cross-validation tests. First, 10% of the
individuals are withheld as a test set. Next, the remaining individuals are repeatedly and randomly split
into two groups, a training set (80%) and a validation set (20%). For each split, the nCOP search heuristic is
run for a range of α values (0 < α < 1) using the individuals comprising the training set. The parameter α is
selected to obtain high coverage of the individuals in the validation sets while maintaining similar coverage
on the training sets (i.e., not overfitting to the training set). Coverage of individuals in the initially withheld
test set is also calculated and confirmed to be similar to the validation sets. (c) Once α is selected, to
avoid overfitting on the entire dataset, nCOP is run 1000 times using 85% of the individuals. (d) Finally, the
subnetworks output across the runs are aggregated and candidate genes are ranked by the number of the
times they appear in the outputted subnetworks.
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Figure S2: Fraction of individuals covered as α varies across all cancers. For each random
split of the individuals, we run our algorithm on the training sets for different values of α, and
plot the fraction of covered individuals in the training (blue) and validation (red) sets. We also
give the number of proteins in the uncovered subgraphs G′ (orange). For each plotted value, the
mean and standard deviation over 100 random splits are shown and the automatically selected α
for the missense mutation data is indicated by a green rhombus. The performances on both the
training and validation sets are much worse when using synonymous mutations compared to when
using missense mutations. Coverage on the validation set for synonymous mutations is consistently
lower for the same values of α across respective cancer types than that for missense mutations,
with maximum possible coverage on the validation set not exceeding 50% in many cases. Further,
it takes significantly more nodes to cover the same fraction of patients when using synonymous
mutations.
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Figure S3: Comparison between nCOP and Hotnet2. For each cancer type, we compute the
precision and recall of the genes returned by nCOP and Hotnet2. For nCOP, we choose a single
threshold to select predicted cancer genes, corresponding to those genes that occur in at least 25%
of the runs. While Hotnet2 achieves slightly greater recall due to the larger number of genes it
highlights, nCOP’s precision using this threshold is superior. nCOP uncovers fewer but potentially
more relevant cancer genes.
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Figure S4: Comparison of nCOP when run on Biogrid to network-agnostic methods across
24 cancers. To make sure that our method is robust with respect to the specific network utilized,
we repeat our entire analysis procedure using the Biogrid network. For each of the 24 cancers,
we compute the log2 ratio of AUPRCs using the top 100 predictions for nCOP and Set Cover (left
panel) and nCOP and MutSigCV (right panel). Our approach nCOP outperforms the network-agnostic
methods in 21 out of 24 of the cancer types.
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Figure S5: Comparison to randomized networks. We use two approaches to randomize the
underlying HPRD network: (1) a classic degree-preserving randomization (stub rewiring) and (2)
node label shuffling where the network structure is maintained but genes can have different degrees
and interactors. For each of the 24 cancers, we compute the log2 ratio of the area under the
precision recall curve using nCOP on the real network and on the randomized network. Performance,
as expected, is worse for both randomizations across all cancers, except, interestingly, for PRAD
with stub rewiring. We speculate that the large number of CCG genes with high degree mutated
in PRAD became connected in a module that was ranked highly by nCOP. In the full version of this
paper, this figure will contain data averaged over multiple randomized networks.
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Figure S6: Novel genes uncovered by nCOP are not due to patients with many mutations.
Plotted for each cancer type are the total number of missense mutations for patients having missense
mutations only in known CCG genes and not in novel genes (left) and the total number of missense
mutations for patients having missense mutations only in novel genes and not in CCG genes (right).
The novel genes uncovered by nCOP are not due to patients with large numbers of mutations.
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